Nicola C Dijon
Overview
Explore the profile of Nicola C Dijon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
12
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ertl F, Kopanchuk S, Dijon N, Veiksina S, Tahk M, Laasfeld T, et al.
J Med Chem
. 2024 Sep;
67(18):16664-16691.
PMID: 39261089
The determination of ligand-receptor binding affinities plays a key role in the development process of pharmaceuticals. While the classical radiochemical binding assay uses radioligands, fluorescence-based binding assays require fluorescent probes....
2.
Talamonti E, Davegardh J, Kalinovich A, van Beek S, Dehvari N, Halleskog C, et al.
Mol Metab
. 2024 May;
85:101931.
PMID: 38796310
Objective: Simultaneous activation of β2- and β3-adrenoceptors (ARs) improves whole-body metabolism via beneficial effects in skeletal muscle and brown adipose tissue (BAT). Nevertheless, high-efficacy agonists simultaneously targeting these receptors whilst...
3.
Bosma R, Dijon N, Zheng Y, Schihada H, Hauwert N, Shi S, et al.
iScience
. 2022 Sep;
25(9):104882.
PMID: 36060054
In this study, we synthesized and evaluated new photoswitchable ligands for the beta-adrenergic receptors β-AR and β-AR, applying an azologization strategy to the first-generation beta-blocker propranolol. The resulting compounds (Opto-prop-1,...
4.
Dijon N, Nesheva D, Holliday N
Methods Mol Biol
. 2021 Jun;
2268:249-274.
PMID: 34085274
An understanding of the kinetic contributions to G protein-coupled receptor pharmacology and signaling is increasingly important in compound profiling. Nonequilibrium conditions are commonly present in vivo, for example, as the...